Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
Phase 2
Completed
- Conditions
- Hay FeverAllergic ConjunctivitisHypersensitivitySeasonal Allergic Rhinitis
- Interventions
- Drug: PlaceboDrug: Bilastine
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 805
- Registration Number
- NCT00574379
- Locations
- 🇺🇸
Lovelace Scientific Resources, Austin, Texas, United States
🇺🇸Live Oak Allergy and Asthma, San Antonio, Texas, United States
🇺🇸MetaClin Research Inc., Austin, Texas, United States
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
Phase 2
Completed
- Conditions
- Hay FeverRhinoconjunctivitisSeasonal Allergic Rhinitis
- Interventions
- Drug: PlaceboDrug: Bilastine
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 502
- Registration Number
- NCT00574210
- Locations
- 🇨🇦
Allied Research International - Cetero Research, Mississauga, Ontario, Canada
Human Mass Balance Study With Bilastine
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-bilastine
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 6
- Registration Number
- NCT00572611
- Locations
- 🇬🇧
Charles River Laboratories Clinical Services Ltd, Origo Centre, Riccarton, Edinburgh, United Kingdom
Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 683
- Registration Number
- NCT00504933
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 522
- Registration Number
- NCT00421109
- Locations
- 🇧🇪
Centre nº 204, Gent, Belgium
🇦🇷Centre nº 107, Buenos Aires, Argentina
🇵🇱Centre nº 507, Krakow, Poland
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
Phase 2
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 75
- Registration Number
- NCT00420082
- Locations
- 🇦🇹
Allergy Center Vienna West, Vienna, Austria
A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 30
- Registration Number
- NCT00419783
- Locations
- 🇺🇸
MDS Pharma Services, Phoenix, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath